Deleterious nonsynonymous single nucleotide polymorphisms in human solute carriers: The first comparison of three prediction methods

School of Environment, Biotechnology Institute, Dalian Jiaotong University, Dalian, 116028, China, .
European Journal of Drug Metabolism and Pharmacokinetics (Impact Factor: 1.56). 05/2012; 38(1). DOI: 10.1007/s13318-012-0095-8
Source: PubMed


Abundant nsSNPs have been found in genes coding for human solute carrier (SLC) transporters, but there is little known about the relationship between the genotype and phenotype of nsSNPs in these membrane proteins. It is unknown which prediction method is better suited for the prediction of nonneutral nsSNPs of SLC transporters. We have identified 2,958 validated nsSNPs in human SLC family members 1-47 from the Ensembl genome database and the NCBI SNP database. Using three different algorithms, 37-45 % of nsSNPs in SLC genes were predicted to have functional impacts on transporter function. Predictions largely agreed with the available experimental annotations. Overall, 76.5, 74.4, and 73.5 % of nonneutral nsSNPs were predicted correctly as damaging by SNAP, SIFT, and PolyPhen, respectively, while 67.4, 66.3, and 76.7 % of neutral nsSNPs were predicted correctly as nondamaging by the three methods, respectively. This study identified many amino acids that were likely to be functionally critical but have not yet been studied experimentally. There was a significant concordance between the predicted results of different methods. Evolutionarily nonneutral (destabilizing) amino acid substitutions are predicted to be the basis for the pathogenic alteration of SLC transporter activity that is associated with disease susceptibility and altered drug/xenobiotic response.

12 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Preclinical Research Network pharmacology, based on the theory of systems biology, is a new discipline that analyzes the biological network and screens out the nodes of particular interest, with the aim of designing poly-target drug molecule. It emphasizes maximizing drug efficacy and minimizing adverse effect via the multiple regulation of the signaling pathway. Coincidentally, almost all traditional Chinese medicine (TCM) and worldwide ethnomedicine exert therapeutic effect by targeting multiple molecules of the human body. In this overview, we offer a critique on the present perception of TCM and network pharmacology; illustrate the utility of network pharmacology in the study of single herb, medicine pair, and TCM formula; and summarize the recent progress of TCM-based drug discovery inspired by network pharmacology. Network pharmacology could be of great help in decreasing drug attrition rate and thus is essential in rational and cost-effective drug development. We also pinpoint the current TCM issues that could be tackled by the flexible combined use of network pharmacology and relevant disciplines.
    Drug Development Research 08/2014; 75(5):299-312. DOI:10.1002/ddr.21214 · 0.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The wide-reaching distributed angiosperm family Ranunculaceae has approximately 2200 species in around 60 genera. Chemical components of this family include several representative groups: benzylisoquinoline alkaloid (BIA), ranunculin, triterpenoid saponin and diterpene alkaloid, etc. Their extensive clinical utility has been validated by traditional uses of thousands of years and current evidence-based medicine studies. Drug metabolism and pharmacokinetic (DMPK) studies of plant-based natural products are an indispensable part of comprehensive medicinal plant exploration, which could facilitate conservation and sustainable utilization of Ranunculaceae pharmaceutical resources, as well as new chemical entity development with improved DMPK parameters. However, DMPK characteristics of Ranunculaceae derived medicinal compounds have not been summarized. Black cohosh (Cimicifuga) and goldenseal (Hydrastis) raise concerns of herbdrug interaction. DMPK studies of other Ranunculaceae genera, e.g., Nigella, Delphinium, Aconitum, Trollius, and Coptis, are also rapidly increasing and becoming more and more clinically relevant. In this contribution, we highlight the up-to-date awareness, as well as the challenges around the DMPK-related issues in optimization of drug development and clinical practice of Ranunculaceae compounds. Herb-herb interaction of Ranunculaceae herb-containing traditional Chinese medicine (TCM) formula could significantly influence the in vivo pharmacokinetic behavior of compounds thereof, which may partially explain the complicated therapeutic mechanism of TCM formula. Although progress has been made on revealing the absorption, distribution, metabolism, excretion and toxicity (ADME/T) of Ranunculaceae compounds, there is a lack of DMPK studies of traditional medicinal genera Aquilegia, Thalictrum and Clematis. Fluorescent probe compounds could be promising substrate, inhibitor and/or inducer in future DMPK studies of Ranunculaceae compounds. A better understanding of the important herb-drug/herb-herb interactions, bioavailability and metabolomics aspects of Ranunculaceae compounds will bolster future natural product-based drug design and the comprehensive investigation of inter-individual inconsistency of drug metabolism.
    Current Drug Metabolism 08/2015; 16(4). DOI:10.2174/1389200216666150803144631 · 2.98 Impact Factor